Novartis to buy out kidney specialist Chinook Therapeutics in $3.5B deal
Novartis is putting down $3.2 billion in cash to acquire kidney-focused biotech Chinook Therapeutics and its two late-stage drugs for a rare chronic kidney disease. The Swiss pharma giant already has a top drug, iptacopan, that it said showed promise in IgA nephropathy, which…#novartis #kidney #vasnarasimhan #atrasentan #unlock
Source: Reuters: Health - Category: Consumer Health News Source Type: news